Eurofins-Cerep SA - Asset Resilience Ratio
Eurofins-Cerep SA (ALECR) has an Asset Resilience Ratio of 13.39% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Also explore balance sheet size of Eurofins-Cerep SA for the complete picture of this company's asset base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2000–2025)
This chart shows how Eurofins-Cerep SA's Asset Resilience Ratio has changed over time. See how leveraged is Eurofins-Cerep SA's balance sheet to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Eurofins-Cerep SA's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see ALECR market cap overview.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €11.92 Million | 13.39% |
| Total Liquid Assets | €11.92 Million | 13.39% |
Asset Resilience Insights
- Moderate Liquidity: Eurofins-Cerep SA has 13.39% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
Eurofins-Cerep SA Industry Peers by Asset Resilience Ratio
Compare Eurofins-Cerep SA's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Guangzhou Kingmed Diagnostics Group Co Ltd
SHG:603882 |
Diagnostics & Research | 0.14% |
|
SMO ClinPlus Co. Ltd.
SHE:301257 |
Diagnostics & Research | 15.78% |
|
Healius Ltd
AU:HLS |
Diagnostics & Research | 0.06% |
|
RHYTHM Biosciences Ltd
AU:RHY |
Diagnostics & Research | 2.74% |
|
Check-Cap Ltd.
NASDAQ:MBAI |
Diagnostics & Research | 2.90% |
|
Sonic Healthcare Ltd
AU:SHL |
Diagnostics & Research | 0.13% |
|
Integral Diagnostics Ltd
AU:IDX |
Diagnostics & Research | 0.03% |
|
Australian Clinical Labs Ltd
AU:ACL |
Diagnostics & Research | 4.11% |
Annual Asset Resilience Ratio for Eurofins-Cerep SA (2000–2025)
The table below shows the annual Asset Resilience Ratio data for Eurofins-Cerep SA.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 13.39% | €11.92 Million ≈ $13.93 Million |
€89.02 Million ≈ $104.07 Million |
+14.06pp |
| 2018-12-31 | -0.67% | €-237.72K ≈ $-277.92K |
€35.26 Million ≈ $41.22 Million |
+28.92pp |
| 2017-12-31 | -29.59% | €-8.93 Million ≈ $-10.44 Million |
€30.18 Million ≈ $35.28 Million |
-22.22pp |
| 2016-12-31 | -7.37% | €-1.91 Million ≈ $-2.23 Million |
€25.94 Million ≈ $30.33 Million |
+15.31pp |
| 2015-12-31 | -22.67% | €-5.71 Million ≈ $-6.68 Million |
€25.18 Million ≈ $29.44 Million |
-24.86pp |
| 2014-12-31 | 2.18% | €500.00K ≈ $584.55K |
€22.90 Million ≈ $26.77 Million |
-9.40pp |
| 2013-12-31 | 11.59% | €3.23 Million ≈ $3.78 Million |
€27.89 Million ≈ $32.60 Million |
-11.39pp |
| 2012-12-31 | 22.97% | €6.96 Million ≈ $8.13 Million |
€30.28 Million ≈ $35.40 Million |
-4.19pp |
| 2011-12-31 | 27.17% | €8.89 Million ≈ $10.39 Million |
€32.72 Million ≈ $38.26 Million |
+3.61pp |
| 2010-12-31 | 23.56% | €8.46 Million ≈ $9.89 Million |
€35.90 Million ≈ $41.97 Million |
-12.21pp |
| 2009-12-31 | 35.77% | €15.85 Million ≈ $18.53 Million |
€44.31 Million ≈ $51.80 Million |
+0.59pp |
| 2008-12-31 | 35.19% | €19.32 Million ≈ $22.59 Million |
€54.91 Million ≈ $64.19 Million |
+3.14pp |
| 2007-12-31 | 32.04% | €20.10 Million ≈ $23.50 Million |
€62.73 Million ≈ $73.34 Million |
+31.62pp |
| 2006-12-31 | 0.42% | €321.00K ≈ $375.28K |
€76.37 Million ≈ $89.29 Million |
-9.48pp |
| 2005-12-31 | 9.90% | €8.29 Million ≈ $9.69 Million |
€83.65 Million ≈ $97.79 Million |
-7.68pp |
| 2004-12-31 | 17.59% | €11.23 Million ≈ $13.13 Million |
€63.87 Million ≈ $74.68 Million |
-20.56pp |
| 2003-12-31 | 38.14% | €19.55 Million ≈ $22.85 Million |
€51.24 Million ≈ $59.91 Million |
+1.01pp |
| 2002-12-31 | 37.14% | €17.72 Million ≈ $20.72 Million |
€47.72 Million ≈ $55.78 Million |
-2.14pp |
| 2001-12-31 | 39.27% | €16.06 Million ≈ $18.78 Million |
€40.90 Million ≈ $47.81 Million |
+13.61pp |
| 2000-12-31 | 25.66% | €6.07 Million ≈ $7.10 Million |
€23.67 Million ≈ $27.67 Million |
-- |
About Eurofins-Cerep SA
Eurofins-Cerep SA provides various drug discovery services to pharmaceutical, biopharmaceutical, and biotechnology companies France and internationally. The company's research services include compound management, and high-throughput screening and profiling. The company was formerly known as Cerep SA and changed its name to Eurofins-Cerep SA in June 2014. Eurofins-Cerep SA was founded in 1989 and… Read more